Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study

Johnson & Johnson (JNJ) reported positive Phase 4 STAR study results for TREMFYA, showing improvement in axial symptoms and reduced MRI-confirmed inflammation in adults with psoriatic arthritis. The study met primary and major secondary endpoints, with significant improvements in disease activity and inflammation measures. JNJ plans to present detailed results at a scientific congress. TREMFYA is a monoclonal antibody targeting IL-23, with a known safety profile.

Johnson & Johnson (JNJ) reported long-term data from the CARTITUDE-2 study, showing 50% of 20 patients with multiple myeloma remained progression-free for five years after a single CARVYKTI infusion. The five-year overall survival rate was 69.2%, with a median progression-free survival of 60.5 months. JNJ is advancing CARVYKTI's evaluation and its broader multiple myeloma portfolio. The stock closed at $270.68, up 0.56%.

Johnson & Johnson reported positive results from clinical trials for Tremfya and Carvykti. Tremfya met primary and secondary endpoints in a psoriatic arthritis study, showing improvement in disease activity scores. Carvykti demonstrated 50% five-year progression-free survival in multiple myeloma patients. JNJ shares were down 0.20% to $270.24 at the time of publication.

Johnson & Johnson (JNJ) extended its 64-year dividend growth streak with a 3.1% quarterly raise, supported by projected $21 billion in free cash flow. The company's oncology drugs, like CARVYKTI and TREMFYA, offset losses from Stelara biosimilars. JNJ's dividend yield is 1.94%, and shares are up 31.11% year-to-date. The company aims for a 65th consecutive hike in 2027, subject to free cash flow and litigation risks.

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.